| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Apimeds Pharmaceuticals US, Inc.$0.74
-0.01 (-1.01%)
D 32Pipeline Score Overvalued Biotech · Clinical
Market Cap
18.86 M
EPS
-0.50
P/E Ratio
-
Value Trade
96.84 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
901.14 K
Operating CF
-2.07 M
Total Assets
141.22 M
Total Liabilities
14.70 M
Equity
126.52 M
D/E Ratio
12,345
11.94 %
Week
-11.24 %
1 Month
1.35 %
3 Month
-37.24 %
6 Month
-62.5 %
5 Year
-62.5 %
All Time
Cash Data
Cash Position
8.98 M
Monthly Burn
689.00 K
Runway
11.7 mo
Burn Trend
StableSEC Filing
May 26, 2026
Overview
Volume
22.89 K
52 Week Range
0.95 - 5.97
% held by Insiders
62.68 %
% held by Institutions
2.97 %
Enterprise Value
15.06 M
Total Shares
12.58 M
Short %
2.15 %
Float Shares
6.85 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D32
Pipeline Score $10M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.5x
rNPV / MCap Top 39%
Micro Cap (rank 554 of 906)
Percentile RankApimeds Pharmaceuticals US, Inc. faces pipeline headwinds (32/100), with $1.6B risk-adjusted pipeline value, led by histamine in Osteoarthritis of the Knee (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| histamine Monoclonal antibody | Osteoarthritis of the Knee | Phase 3 | NCT01112722 | 68% | $1.3B | COMPLETED | 363 | - | - | Dec 1, 2016 | - | Dec 13, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in APUS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
APUS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
APUS▲ +59.6%on this news
Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual Report Matawan, N.J.
Apimeds Pharmaceuticals announced it received a notice of non-compliance from NYSE Regulation regarding the late filing of its Form 10-K for the fiscal year ending December 31, 2025. The company is under scrutiny to complete its filing by April 30, 2026, following which the trading of its stock is designated with a '.LF' for late filings. Should the company fail to correct this within the specified periods, it risks suspension or delisting from the exchange.
Read more →APUSInscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
Inscobee Inc. and Apimeds, Inc. have announced the removal of several board members and the appointment of new directors for Apimeds Pharmaceuticals US, Inc. This change follows a Written Consent delivered by stockholders holding a majority of voting power. MindWave Innovations has challenged these actions, alleging breaches of a Support Agreement, which the companies strongly deny.
Read more →APUS▼ -12.3%on this news· ran to -90% by day 3shared move
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery MATAWAN, N.J. & SEOUL, South Kor
Apimeds Pharmaceuticals US Inc. (APUS) has announced a material breach of its merger agreement by Inscobee Inc. and its subsidiary, which initiated a hostile takeover in violation of their contractual commitments. Inscobee claims to have removed the company's board without authorization, prompting APUS to prepare an emergency legal action in Delaware to contest the changes and maintain its board structure. The company is also engaging legal counsel in Korea to address Inscobee's actions under both U.S. and Korean law. APUS emphasizes its intention to defend shareholder interests and fulfill its merger objectives.
Read more →APUS▼ -24.1%on this news
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
Apimeds Pharmaceuticals and Lōkahi Therapeutics announced a Type C meeting with the FDA to discuss LT-100, a biologic candidate for osteoarthritis treatment. This meeting, scheduled for May 4, 2026, aims to align on development strategies for the product, which is based on honeybee venom and has been previously approved in South Korea. The companies are enhancing the manufacturing process and integrating historical data to support its advancement in the U.S.
Read more →APUSApimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a merger with MindWa
Apimeds Pharmaceuticals has announced a merger with MindWave Innovations, combining their expertise in biotechnology and digital asset treasury solutions. The merger, accompanied by a concurrent PIPE financing of $100 million, aims to enhance Apimeds' clinical programs while expanding MindWave's digital asset infrastructure. This strategic alliance intends to capitalize on both companies' strengths, positioning them in rapidly growing sectors. However, potential integration issues and market volatility remain as risks.
Read more →APUSApimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division MATAWAN, N.J.
Apimeds Pharmaceuticals has announced the expansion of its leadership team with the appointments of Dr. Susan Kramer as Senior Vice President of Development and Brian Peters as Head of its ai² division. Dr. Kramer, who has extensive experience in biopharmaceutical research, will oversee product development activities, while Peters will focus on strategic positioning and the launch of the ai² platform. These additions are seen as strengthening operational leadership at an important time for the company's Apitox program, a bee venom-based therapeutic being developed for osteoarthritis knee pain treatment.
Read more →APUSApimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
Apimeds Pharmaceuticals US, Inc. has successfully closed its initial public offering, raising $13.5 million by selling 3,375,000 shares at $4.00 each. The funds will be used to support a Phase III clinical trial for knee osteoarthritis and other corporate initiatives. The shares began trading on the NYSE American under the ticker APUS on May 9, 2025.
Read more →APUSApimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Apimeds Pharmaceuticals US, Inc. has announced the pricing of its initial public offering, offering 3,375,000 shares at $4.00 each, aiming to raise $13.5 million. The funds will support a Phase III clinical trial for knee osteoarthritis and other studies. The offering is set to close on May 12, 2025, with shares trading on NYSE American starting May 9, 2025.
Read more →Competitive Position
How APUS ranks across every disease it competes inCompetitive Position is a premium feature
See how APUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial